Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04525222
Other study ID # RG1121054
Secondary ID NCI-2020-0545410
Status Completed
Phase Phase 1
First received
Last updated
Start date May 9, 2022
Est. completion date April 12, 2023

Study information

Verified date March 2024
Source Fred Hutchinson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial investigates a new smartphone application (called Actify) for improving population-level smoking cessation and mood management. Actify delivers behavioral activation therapy for depression as part of a smoking cessation intervention and will be compared to another smoking cessation smartphone application that is based on current clinical practice guidelines. Participants will be randomly assigned to receive one of two smartphone applications and accompanying text notifications to help with quitting smoking and improved mood.


Description:

OUTLINE: Participants are randomized to 1 of 2 arms. ARM I: Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications. ARM II: Participants use United States (US) Clinical Practice Guidelines (USCPG) app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications. After completion of study, participants are followed up at 6 months.


Recruitment information / eligibility

Status Completed
Enrollment 242
Est. completion date April 12, 2023
Est. primary completion date December 19, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Current smoker, averaging at least 5 cigarettes/day for the last 30 days - Interested in quitting smoking in the next 30 days - Experience downloading and using one or more apps on their smartphone - Either screens negative (Patient Health Questionnaire - 9 Item [PHQ-9] score 0-4) for depression or screens positive for mild to moderate current depressive symptoms (PHQ-9 score 5-19) - Willing and able to complete all study activities - Comfortable reading and writing in English - Have a mobile data plan and/or access to WiFi to support the use of the Actify app - Reside in the US - Have a smartphone either an iPhone (running iOS version 11 or higher) or an Android phone (running version 5.0 or higher) Exclusion Criteria: - Currently receiving behavioral treatment for depression (e.g., psychotherapy) - Current use of a depression app - Severe depression (PHQ-9 >= 20) - Receiving other treatment for smoking cessation - Previous use of the QuitGuide app - Current or recent (within the past year) enrollment in a Fred Hutch smoking cessation study - Employees/family of investigator or study center - Member of the same household as another participant - Woman who is pregnant or breastfeeding, or planning to become pregnant - Currently incarcerated - Is ineligible per fraud prevention protocol

Study Design


Related Conditions & MeSH terms

  • Cigarette Smoking-Related Carcinoma

Intervention

Other:
Health Promotion and Education
Receive motivational messages and smoking cessation information via text notifications
Behavioral:
Smoking Cessation Intervention (Actify app)
Use Actify app
Smoking Cessation Intervention (Current Standard Care app)
Use (USCPG) Current Standard Care app
Other:
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Satisfaction With Assigned Treatment on the Treatment Satisfaction Survey Overall treatment satisfaction is reported on a Likert-type scale, with response choices ranging from "not at all=1" to "very much=5". Higher values are associated with higher level of satisfaction. At 8 weeks post-randomization
Primary Application (App) Utilization Number of app openings during the 8-week treatment period. At 8 weeks post-randomization
Secondary Biochemically-confirmed 30-day PPA From Smoking Self-reported 30-day smoking abstinence at 8 weeks, confirmed via expired carbon monoxide (CO<6ppm) At 8 weeks post-randomization
Secondary Self-reported 30-day PPA From Smoking Self-reported 30-day abstinence on the survey question of "Have you smoked at all, even a puff, in the last 30 days?" At 6 months post-randomization
Secondary Biochemically-confirmed 30-day PPA From Smoking Self-reported 30-day smoking abstinence at 6 months, confirmed via expired carbon monoxide (CO<6 ppm) At 6 months post-randomization
Secondary Self-reported 7-day PPA From Smoking Self-reported 7-day abstinence on the survey question of "When was the last time you smoked, or even tried, a cigarette?" At 8 weeks post-randomization
Secondary Biochemically Confirmed 7-day PPA From Smoking Self-reported 7-day abstinence from smoking, confirmed via expired carbon monoxide (CO < 6ppm) At 8 weeks post-randomization
Secondary Self-reported 7-day PPA From Smoking Self-reported 7-day abstinence on the survey question of "When was the last time you smoked, or even tried, a cigarette?" At 6 months post-randomization
Secondary Biochemically Confirmed 7-day PPA From Smoking Self-reported 7-day abstinence from smoking, confirmed via expired carbon monoxide (CO < 6ppm) At 6 months post-randomization
Secondary Self-reported 30-day PPA From Smoking Cigarettes and Other Non-medicinal Nicotine/Tobacco Products, Including E-cigarettes Self-reported 30-day abstinence on the survey questions of "Have you smoked at all, even a puff, in the last 30 days?" & "In the last 30 days, how often did you use any kind of e-cigarette or vaping product?" & "In the last 30 days, how often did you use any other tobacco products such as chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, and kreteks?" At 8 weeks post-randomization
Secondary Biochemically Confirmed 30-day PPA From Smoking Cigarettes and Other Non-medicinal Nicotine/Tobacco Products, Including E-cigarettes Self-reported abstinence from cigarettes and other non-medicinal nicotine/tobacco products, including e-cigarettes, confirmed via at home saliva cotinine test and expired carbon monoxide (CO < 6ppm) At 8 weeks post-randomization
Secondary Self-reported 30-day PPA From Smoking Cigarettes and Other Non-medicinal Nicotine/Tobacco Products, Including E-cigarettes Self-reported 30-day abstinence on survey questions of "Have you smoked at all, even a puff, in the last 30 days?" & "In the last 30 days, how often did you use any kind of e-cigarette or vaping product?" & "In the last 30 days, how often did you use any other tobacco products such as chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, and kreteks?" At 6 months post-randomization
Secondary Biochemically Confirmed 30-day PPA From Smoking Cigarettes and Other Non-medicinal Nicotine/Tobacco Products, Including E-cigarettes Self-reported abstinence from cigarettes and other non-medicinal nicotine/tobacco products, including e-cigarettes, confirmed via at home saliva cotinine test and expired carbon monoxide (CO < 6ppm) At 6 months post-randomization
Secondary Change in Depressive Symptoms Via Patient Health Questionnaire-8 (PHQ-8) The Patient Health Questionnaire-8 (PHQ-8) is an assessment of depressive symptoms used to detect symptom changes over time as a result of treatment. The PHQ-8 asks the number of days in the past 2 weeks the respondent had experienced a particular depressive symptom. Possible answers are "not at all" or "several days" or "more than half the days" or "nearly every day," with points (0 to 3) assigned to each category. The scores for each item are summed to produce a total score between 0 and 24 points. A total score of 0 to 4 represents no significant depressive symptoms. A total score of 5 to 9 represents mild depressive symptoms; 10 to 14, moderate; 15 to 19, moderately severe; and 20 to 24, severe. Baseline to 8 weeks
Secondary Self-reported 30-day Point Prevalence Abstinence (PPA) From Smoking Self-reported 30-day abstinence on the survey question of "Have you smoked at all, even a puff, in the last 30 days?" At 8 weeks post-randomization
Secondary Change in Behavioral Activation Subscale Score on the Behavioral Activation for Depression Scale (BADS) The Behavioral Activation for Depression Scale (BADS) is a 25-item scale used to track changes in behaviors hypothesized to underlie depression and specifically targeted for change by behavioral activation. BADS items are rated on a 7-point scale ranging from 0 (not at all) to 6 (completely). The behavioral activation subscale contains 7 items, with a scoring range of 0 to 42. Change scores reflect the value of the BADS behavioral activation subscale score at 8-week follow-up minus the baseline score. Positive change values indicate an increase in behavioral activation (i.e, an improvement), whereas negative scores indicate a decrease in behavioral activation. Baseline to 8 weeks post-randomization
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Recruiting NCT05121051 - Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers Phase 2
Not yet recruiting NCT06386432 - EQQUAL-NM for the Promotion of Smoking Cessation in Sexual and Gender Minority Young Adults in New Mexico N/A
Active, not recruiting NCT02964182 - Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers N/A
Completed NCT04510077 - SmartQuit Program for Smoking Cessation N/A
Recruiting NCT06230159 - Evaluating the Impact of Synthetic Cooling Agents in Combustible Cigarettes on Smoking Perceptions and Use N/A
Completed NCT05455086 - Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study N/A
Recruiting NCT06010355 - Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable Communities N/A
Completed NCT05236894 - Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population Early Phase 1
Recruiting NCT05825001 - Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers N/A
Not yet recruiting NCT06213532 - CONNECTing to LungCare N/A
Recruiting NCT03856515 - Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes N/A
Completed NCT03480373 - Electronic Cigarette Use During Pregnancy
Not yet recruiting NCT06055231 - PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis Phase 1
Active, not recruiting NCT04308759 - An Innovative Conversational Agent (Quitbot) for Smoking Cessation Phase 3
Active, not recruiting NCT04972513 - Impact of E-cigarette Use on the Body
Withdrawn NCT05024955 - Evaluating Shared Decision-Making for Lung Cancer Screening Among Chinese Populations in the United States
Completed NCT05227027 - Pilot Trial of a Game Embedded in a Smartphone App for Smoking Cessation N/A
Completed NCT04502524 - Website Smoking Cessation Intervention for the Promotion of Smoking Cessation in Low-Income Veterans Phase 1
Completed NCT03402230 - Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers Early Phase 1